Positron (OTCMKTS:POSC – Get Free Report) is one of 74 public companies in the “Electromedical equipment” industry, but how does it compare to its peers? We will compare Positron to related companies based on the strength of its earnings, valuation, dividends, institutional ownership, profitability, risk and analyst recommendations.
Earnings and Valuation
This table compares Positron and its peers top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Positron | $740,000.00 | -$1.64 million | -12.13 |
Positron Competitors | $1.00 billion | $85.30 million | 5.52 |
Positron’s peers have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Positron | -300.00% | N/A | -89.57% |
Positron Competitors | -331.31% | -92.24% | -30.04% |
Institutional and Insider Ownership
44.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 17.2% of Positron shares are owned by insiders. Comparatively, 14.7% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Positron has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Positron’s peers have a beta of 17.00, suggesting that their average stock price is 1,600% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Positron and its peers, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Positron | 0 | 0 | 0 | 0 | N/A |
Positron Competitors | 270 | 803 | 2019 | 109 | 2.61 |
As a group, “Electromedical equipment” companies have a potential upside of 3,351.31%. Given Positron’s peers higher possible upside, analysts clearly believe Positron has less favorable growth aspects than its peers.
Summary
Positron peers beat Positron on 7 of the 10 factors compared.
About Positron
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.
Receive News & Ratings for Positron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Positron and related companies with MarketBeat.com's FREE daily email newsletter.